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ACCEPTED MANUSCRIPT 3 induced seizure. All 15 patients were children suggesting that young age is a risk factor for DRE after CSA-induced seizures. Initial CSA-induced seizures occurred at an average of 1.6 ± 1.1 months after transplant and seizure recurrence 9.2 ± 8.0 months after transplant. All reported CSA routes of administration (n=6) were intravenous and 7 of 9 (78%) reported CSA blood levels above the therapeutic range. The incidence of MTS (40%) in these 15 patients was significantly higher than the incidence in the general DRE population (24%) and was most effectively treated via epilepsy surgery.
Conclusions
The use of cyclosporine for GvHD prophylaxis and treatment following transplantation may cause seizures that lead to DRE. Although discontinuation and dose decrease of CSA often reverses adverse neurological events, initial CSA-induced seizures may cause irreversible damage that leads to increased risk of DRE development.
INTRODUCTION
Drug-resistant epilepsy (DRE) occurs in 20-30% of all patients who develop epilepsy and can occur from diverse causes. Cyclosporine-A (CSA) is a common immunosuppressant drug utilized to prevent graft-versus-host disease (GvHD) in patients who undergo solid organ or bone marrow transplantation. Twenty to forty percent of transplant patients experience a central nervous system (CNS) complication due to CSA, most commonly in the first few months posttransplant. [1, 2] A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 Acute CSA-induced neurotoxic effects include headache, encephalopathy, mental status changes, visual disturbances, akinetic mutism, stroke and seizures. [3] [4] [5] [6] [7] [8] [9] Seizures, the second most common of CSA-induced neurotoxic events, have been reported in 2.5-8.4% of pediatric and 1.5-5.5% of adult post-transplant patients. [2, [10] [11] [12] 
CASE REPORT

Initial presentation and development of T-cell lymphoma (Non-Hodgkin's lymphoma)
A 28-year-old man with a history of common variable immunodeficiency (CVID) and
panhypogammaglobulinemia was found to have liver lesions and adenopathy near the aortic arch. A liver biopsy revealed T-cell lymphoma, and he was subsequently treated with four cycles
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ACCEPTED MANUSCRIPT 5 of CHOP chemotherapy (cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisone) and two cycles of DHAP chemotherapy (dexamethasone, high dose cytarabine and cisplatin). -Hodgkin's lymphoma, NHL) progression, and therefore, the patient underwent bone marrow transplant.
Chemotherapy had no significant effect on T-cell lymphoma (Non
Allogenic bone marrow transplant
The patient began an immunosuppressive conditioning regimen of cyclophosphamide and total body irradiation (TBI) prior to an allogenic HLA-matched related bone marrow transplant from his sister and engrafted by day 20. Post-transplant, he received monthly intravenous immunoglobulin (IVIG) infusions and 550 mg of cyclosporine daily. The patient developed graft-versus-host disease (GvHD) of the liver, and the patient was started on prednisone and continued cyclosporine. While tapering prednisone, the patient was hospitalized for herpes simplex I of the mouth and nose and bacterial sinusitis, treated successfully with acyclovir and cefepime, respectivelyboth suspected to have occurred due to a weakened immune system from prednisone and cyclosporine.
Cyclosporine toxicity, neurological effects, and initial seizure
Days after his hospitalization for herpes simplex and sinusitis, at 7. were intravenous and 7 of 9 (78%) reported CSA blood levels above the therapeutic range. MTS on neuroimaging was observed in 40% (n=6) with one confirmed by pathology. Only 13% (n=2) underwent a temporal lobectomy and amygdalohippocampectomy. Latest follow-ups of an average 6.9 years' post-transplant reveal that 80% (n=12) continued to have seizures while the two patients with anterior temporal lobectomies were seizure-free. One patient died five months' post-transplant due to deteriorating neurological status.
A C C E P T E D M A N U S C R I P T Table 2) were pediatric patients (less than 18 years old) at the time of transplantation and CSA administration. Interestingly, the patient described here in our report is an adult known to have
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ACCEPTED MANUSCRIPT 10 developed DRE following post-transplant CSA-induced neurotoxicitya presentation uncommonly found adults. In the general population, DRE in adults is much less common compared to in children. [27] Additionally, most adults that go on to develop DRE have had medically-controlled epilepsy since age 12 or younger (about 80%). [18] Although drugresistance etiology in epilepsy is multifactorial and not well understood, some have hypothesized that DRE pathogenesis is thought to arise from antiseizure drugs not reaching their target (predominately voltage-gated ion channels and GABA receptors), an alteration of the antiseizure drug targets, and/or antiseizure drugs binding incorrect targets. [28, 29] 
Oral vs intravenous cyclosporine
Of the six reported cyclosporine administrations that led to DRE in our review ( Table 2) , all experienced CSA neurotoxicity while on intravenous CSA. Whether intravenous CSA contributes to a higher incidence of neurotoxicity than oral CSA is unclear. However, past studies have found that microemulsion oral CSA (Neoral) causes fewer neurological complications than intravenous CSA with no difference in acute rejection occurrence. [30, 31] .
Although the adult patient we reported here was given oral CSA, the use of oral CSA instead of
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ACCEPTED MANUSCRIPT 11 intravenous CSA may reduce the chance of CSA-induced seizures, especially in those patients presenting with existing risk factors for DRE.
Cyclosporine discontinuation, reduction and substitution
Four of the seven patients, in addition to the patient we presented here, were discontinued on CSA following their first CSA-induced seizure and placed on tacrolimus (or a milder immunosuppressant) ( In these cases, epilepsy surgery is the most effective means for treating DRE.
DISCLOSURES
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. The patient gave signed consent for the release of his health information in the context of this case study. He is a subject of our research protocol that has been reviewed and accepted by the University of Iowa's Institutional Review Board (IRB). Figure 1 
TABLES
